Purdue invests $30 million in Infinity
This article was originally published in Scrip
Infinity Pharmaceuticals has issued two million shares of its common stock to Purdue Pharma, which bought the stock for $15 per unit, or $30 million in total. The sale follows the strategic alliance that Infinity entered into with Purdue and Mundipharma last November (Scrip Online, November 25th, 2008). Under the agreement Purdue may buy up to six million shares between the beginning of this year and the end of June 2012. Purdue has now invested $75 million in Infinity equity financing and has made a $50 million line of credit available to the company. Draws from the loan facility may be made at any time after April 1st this year and must be repaid with interest by January 7th, 2019. Infinity now expects to have sufficient cash to fund its current operations, R&D and commercial plans until the end of 2012.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.